南新制药(688189.SH)拟以部分超募资金投建“帕拉米韦生产基地三期工程项目”变更为“NX-2016”等5个项目
格隆汇3月26日丨南新制药(688189.SH)公布,公司原“帕拉米韦生产基地三期工程项目”投资总额为人民币4.31亿元,其中拟使用超募资金3.26亿元,拟由公司和全资子公司广州南鑫药业有限公司在广州南鑫药业有限公司厂区内实施,计划工程建筑物总占地面积9,314.00m2,总建筑面积33,285.00m2。该项目尚未提交股东大会审议通过。
公司于2021年3月26日召开第一届董事会第二十一次会议、第一届监事会第十六次会议审议通过了《关于使用部分超募资金投资建设“帕拉米韦生产基地三期工程项目”变更为“NX-2016”等5个项目的议案》,具体调整如下:
公司拟将部分超募资金3.26亿元用于“NX-2016”等5个项目,其中:NX-2016项目计划使用超募资金7561.33万元;GK激活剂项目计划使用超募资金6331.79万元;JAK3抑制剂项目计划使用超募资金8412.14万元;P2X3拮抗剂项目计划使用超募资金8342.44万元;研发实验室建设项目计划使用超募资金1943.03元,剩余部分由公司以自有资金或自筹资金投入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.